Mesothelioma Expert Mary Hesdorffer Advocates Before British Parliament

Mary at Parliament

Mary Hesdorffer, NP with Laurie Kazan-Allen, Dan Sterman, MD, and Jim Sheridan in front of the UK Parliament.

Meso Foundation’s executive director, Mary Hesdorffer, Nurse Practitioner, is in London and wanted to share with you that she just spoke at the annual asbestos seminar of the All Party Parliamentary Group on Occupational Safety and Health in the House of Commons.  Her talk entitled, Mobilizing for a Mesothelioma Cure, stresses how funding research is the key to eliminating mesothelioma.

“I am thrilled to be able to represent the Meso Foundation and the role that it has in funding the most promising peer-reviewed research from around the globe,” said Mary. The Meso Foundation has funded researchers in the United Kingdom and six other countries because we believe that it is necessary to collaborate in order to find a cure for mesothelioma.

Join our cause in the fight against mesothelioma. Learn more about how you can get involved.

Personalized Medicine and Mesothelioma – Are We There Yet?

personalized_medicine_mesothelioma

Personalized medicine is the ability to select a biologic target and direct therapy against this target.  It is associated with improved outcomes in a number of tumor types. The most startling was the development of Gleevec which targets CKit in gastrointestinal stromal tumors. The field has since grown by leaps and bounds. We are making progress in mesothelioma, too.

An example of what I’m talking about is displayed in the presentation made by one of our grant recipients, Liang-Chuan (Steve) Wang, Ph.D., at our International Symposium on Malignant Mesothelioma.

In his presentation of his Foundation-funded grant, Dr. Wang and his colleagues at UPenn identified a gene that may be responsible for chemotherapy resistance in mesothelioma patients to Pemetrexed (Alimta) and cisplatin. As per Dr. Wang, this may identify a group of patients who may need higher doses or longer duration of therapy or perhaps should be encouraged to try new drugs. This is step one and Dr. Wang has assured us that he will continue to work on the concept and in the future hopes that it will lead to a clinical trial.

Another example is the work currently underway to exploit mesothelin as a target and way into the malignant cell. Many of you have met patients at our symposium who have benefited from some of these trials and I remain excited and committed to stewarding patients through the clinical trials system to ensure that they know of all opportunities to participate in cutting edge research. Please take a moment to visit the research section on our website to see how the Meso Foundation has funded grants that have laid the groundwork upon which much of what you read about in mesothelioma news has been built upon.

To further advance our ability to get to the point of personalized medicine the Foundation will continue to foster communication among clinician, basic scientists, pathologists and members of biotech and pharmaceutical companies to disseminate information, as well as fund the work that will take us to the next level. Early on, we partnered with Dr. Mike Becich to ensure that the Mesothelioma Virtual Tissue Bank became a reality and we are proud to say that our efforts have paid off. Mesothelioma researchers now have access to mesothelioma tissue to conduct their experiments and further their scientific endeavors.